Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 2, 2017, Pages 273-281.e1

  Khalaf, Natalia ^a,b   Ying, Jun ^a   Mittal, Sahil ^a,b   Temple, Sarah ^a   Kanwal, Fasiha ^a,b   Davila, Jessica ^a   El Serag, Hashem B ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AFP; Epidemiology; MELD Score; Outcomes; Prognosis

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HEPATITIS C; HISTORY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SURVIVAL TIME; UNITED STATES; VETERAN; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGICAL MONITORING; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; EPIDEMIOLOGICAL MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; UNITED STATES;

EID: 85005958919     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.07.033     Document Type: Article

References (34)

1. 1 Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence — SEER 9 Regs research data, Nov 2009 Sub (1973–2007), 2010, National Cancer Institute, Bethesda, MD.
2. 2 El-Serag, H.B., Hepatocellular carcinoma. N Engl J Med 365 (2011), 1118–1127.
3. 3 Tan, D., Yopp, A., Beg, M.S., et al. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 38 (2013), 703–712.
4. 4 Cabibbo, G., Enea, M., Attanasio, M., et al. A metaanalysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51 (2010), 1274–1283.
5. 5 Cabibbo, G., Maida, M., Genco, C., et al. Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study. World J Hepatol 4 (2012), 256–261.
6. 6 Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma. Lancet 379 (2012), 1245–1255.
7. 7 Giannini, E.G., Farinati, F., Ciccarese, F., et al. Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 61 (2015), 184–190.
8. 8 Yeung, Y.P., Lo, C.M., Liu, C.L., et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 100 (2005), 1995–2004.
9. 9 Chen, J.G., Parkin, D.M., Chen, Q.G., et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 10 (2003), 204–209.
10. 10 Davila, J.A., Henderson, L., Kramer, J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 154 (2011), 85–93.
11. 11 Trevisani, F., De, N.S., Rapaccini, G., et al. Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97 (2002), 734–744.
12. 12 Sherman, M., Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis 11 (2007), 817–837.
13. 13 Davila, J.A., Weston, A., Smalley, W., et al. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 41 (2007), 777–782.
14. 14 Bruix, J., Sherman, M., Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
15. 15 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
16. 16 Mittal, S., El-Serag, H.B., Sada, Y.H., et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 14 (2016), 124–131.
17. 17 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001), 2486–2497.
18. 18 Ascha, M.S., Hanouneh, I.A., Lopez, R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51 (2010), 1972–1978.
19. 19 Singal, A.G., El-Serag, H.B., Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 13 (2015), 2140–2151.
20. 20 Llovet, J.M., Bru, C., Bruix, J., Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999), 329–338.
21. 21 Pawarode, A., Voravud, N., Sriuranpong, V., et al. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol 21 (1998), 386–391.
22. 22 Wong, L.L., Limm, W.M., Severino, R., et al. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6 (2000), 320–325.
23. 23 Yuen, M.F., Cheng, C.C., Lauder, I.J., et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 31 (2000), 330–335.
24. 24 Trevisani, F., De, N.S., Rapaccini, G., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97 (2002), 734–744.
25. 25 Trevisani, F., Cantarini, M.C., Labate, A.M., et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 99 (2004), 1470–1476.
26. 26 El Serag, H.B., Siegel, A.B., Davila, J.A., et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 44 (2006), 158–166.
27. 27 Llovet, J.M., Bruix, J., Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 14 (2000), 991–1008.
28. 28 Bruix, J., Llovet, J.M., Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35 (2002), 519–524.
29. 29 Llovet, J.M., Burroughs, A., Bruix, J., Hepatocellular carcinoma. Lancet 362 (2003), 1907–1917.
30. 30 Ioannou, G.N., Perkins, J.D., Carithers, R.L. Jr., Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 134 (2008), 1342–1351.
31. 31 Cottone, M., Virdone, R., Fusco, G., et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology 96 (1989), 1566–1571.
32. 32 Barbara, L., Benzi, G., Gaiani, S., et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 16 (1992), 132–137.
33. 33 McGowan, C.E., Edwards, T.P., Luong, M.U., et al. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol 13 (2015), 799–804.
34. 34 Dalton-Fitzgerald, E., Tiro, J., Kandunoori, P., et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 13 (2015), 791–798.